Advertisement

Topics

Chi-Med, AstraZeneca start phase III trial of savolitinib in papillary renal cell carcinoma

05:37 EDT 30 Jun 2017 | Pharmaceutical Business Review

Chi-Med and AstraZeneca have commenced a phase 3 study of their c-MET receptor tyrosine kinase inhibitor savolitinib for the treatment of papillary renal cell carcinoma (PRCC).

Original Article: Chi-Med, AstraZeneca start phase III trial of savolitinib in papillary renal cell carcinoma

NEXT ARTICLE

More From BioPortfolio on "Chi-Med, AstraZeneca start phase III trial of savolitinib in papillary renal cell carcinoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...